Navigation Links
MEDRAD® Announces New Head of Interventional Business
Date:3/29/2011

WARRENDALE, Pa., March 29, 2011 /PRNewswire/ -- Today MEDRAD, INC. announced that Jack Darby has joined the company as vice president of MEDRAD Interventional. In his new role, Darby will act as general manager of both the diagnostic and therapeutic lines of the business on a global scale, and will also join MEDRAD's executive leadership team.  

(Photo:  http://photos.prnewswire.com/prnh/20110329/NE73380 )

(Logo: http://photos.prnewswire.com/prnh/20040309/MEDRADLOGO)

Darby brings almost 20 years of experience in the medical device industry to the role, with most of those years in the interventional cardiology space. He comes to MEDRAD from AGA Medical Corporation, where he most recently served as senior vice president of Global Marketing and Distributor Sales, gaining deep experience in the field of the structural heart. Prior to AGA, Darby spent over 15 years at Cordis, a Johnson & Johnson company, starting as an angiographic sales representative. His leadership ability, sales/marketing acumen and international experience ultimately resulted in his role as vice president of commercial operations and global stent marketing.

"Jack's broad base of experience in the interventional space and combination drug-device products will greatly complement our patient-focused goals for the interventional business," says MEDRAD President and CEO Sam Liang. "With the support of his leadership, we plan to extend our product innovation and customer satisfaction footprint within this growing, global market."

With manufacturing facilities in both Minneapolis, MN and Pittsburgh, PA, MEDRAD Interventional manufactures and markets segment-leading medical devices such as AngioJet® Thrombectomy Systems, MEDRAD Avanta® Fluid Management Injector Systems and catheters, Mark V ProVis® Angiographic Contrast Injectors, FETCH® Aspiration Catheters and the GuardDOG® Occlusion System.

About MEDRAD, INC.

MEDRAD, INC. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. MEDRAD is a two-time recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence (2003 and 2010). The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer HealthCare. More company information is available at www.medrad.com.

Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Forward-looking statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'/>"/>
SOURCE MEDRAD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective
2. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
3. Boston Scientific Announces Its ACC 2011 Schedule
4. Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements
5. Dendreon Announces Webcast Presentations at Upcoming Conferences
6. Diversified Medical Equipment & Supplies Corporation Announces New Home Care Medical Supply Division
7. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
8. JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
9. Ascension Orthopedics Announces Market Release of TITAN™ Modular Shoulder Fracture Prosthesis
10. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
11. Everist Genomics Announces Worldwide Availability of OncoDefender™-CRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Executive Officer of the Company is scheduled to present on Tuesday, ... and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... , ... Providing broad access to life-saving drugs and rewarding the innovators who ... to address this problem. , That was the message from Dana Goldman, PhD, Leonard ... University of Southern California, who served as the keynote speaker for Western University of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke ... young adults, has kicked off its 4th annual Forum for Innovative Treatment Solutions ... is “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ 2017 ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t ... the next project in the company’s esteemed VISION House demonstration project series. Manifesting the ... the amount of resources they need to live affordably and abundantly without unduly taxing ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover Symmetry , ... , an active lifestyle company that provides Human Performance Training and education to ... offers, first responders, military officers and others in service through the development and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical ... Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual ... healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, share ...
Breaking Medicine News(10 mins):